Page 72 - 南京医科大学学报自然科学版
P. 72

第42卷第10期
               ·1414 ·                           南 京    医 科 大 学 学         报                        2022年10月


                   cet Diabetes Endocrinol,2019,7(6):429-441         with sodium⁃glucose co⁃transporter⁃2 inhibitors[J]. Dia⁃
             [9] HERNANDEZ M,SULLIVAN R D,MCCUNE M E,et al.          betes Obes Metab,2021,23(9):2077-2089
                   Sodium⁃glucose cotransporter⁃2 inhibitors improve heart  [20] CAPOLONGO G,CAPASSO G,VIGGIANO D. A shared
                   failure with reduced ejection fraction outcomes by reduc⁃  nephroprotective mechanism for renin⁃angiotensin⁃system
                   ing edema and congestion[J]. Diagnostics(Basel),2022,  inhibitors,sodium ⁃ glucose co ⁃ transporter 2 inhibitors,
                   12(4):989                                         and vasopressin receptor antagonists:immunology meets
             [10] 胡   健,李    英,王晓琴. 六种肾小球滤过率估算公式                     hemodynamics[J]. Int J Mol Sci,2022,23(7):3915

                   用于多发性骨髓瘤患者肾功能评估的一致性分析[J].                    [21] XUAN M Y,PIAO S G,DING J,et al. Dapagliflozin alle⁃
                   山西医科大学学报,2019,50(10):1364-1373                    viates renal fibrosis by inhibiting RIP1⁃RIP3⁃MLKL⁃me⁃
             [11] KINGUCHI S,WAKUI H,ITO Y,et al. Improved home      diated necroinflammation in unilateral ureteral obstruction
                   BP profile with dapagliflozin is associated with ameliora⁃  [J]. Front Pharmacol,2021,12:798381
                   tion of albuminuria in Japanese patients with diabetic ne⁃  [22] ELKAZZAZ S K,KHODEER D M,EL FAYOUMI H M,
                   phropathy:the Yokohama add ⁃ on inhibitory efficacy of  et al. Role of sodium glucose cotransporter type 2 inhibi⁃
                   dapagliflozin on albuminuria in Japanese patients with  tors dapagliflozin on diabetic nephropathy in rats:inflam⁃
                   type 2 diabetes study(Y⁃AIDA study)[J]. Cardiovasc Di⁃  mation,angiogenesis and apoptosis[J]. Life Sci,2021,
                   abetol,2019,18(1):110                             280:119018
                                                                                                    +
                                                                                                         +
             [12] KAWABATA N,OKADA K,ANDO A,et al. Comparison   [23] ZHUANG R,MENG Q,MA X,et al. CD4 FoxP3 CD73  +
                   of the effects of frequent versus conventional nutritional  regulatory T cell promotes cardiac healing post⁃myocardi⁃
                   interventions in patients with type 2 diabetes mellitus:a  al infarction[J]. Theranostics,2022,12(6):2707-2721
                   randomized,controlled trial[J]. J Diabetes Investig,  [24] HU M,ROGERS N M,LI J,et al. Antigen specific regula⁃
                   2022,13(2):271-279                                tory T cells in kidney transplantation and other tolerance
             [13] DEFRONZO R A,REEVES W B,AWAD A S. Pathophys⁃       settings[J]. Front Immunol,2021,12:717594
                   iology of diabetic kidney disease:impact of SGLT2 inhibi⁃  [25] ALI R,PATEL S,HUSSAIN T. Angiotensin type 2 recep⁃
                   tors[J]. Nat Rev Nephrol,2021,17(5):319-334       tor activation limits kidney injury during the early phase
             [14] RAM C,JHA A,GHOSH A,et al. Targeting NLRP3 in⁃     and induces Treg cells during the late phase of renal isch⁃
                   flammasome as a promising approach for treatment of dia⁃  emia[J]. Am J Physiol Renal Physiol,2021,320(5):
                   betic nephropathy:preclinical evidences with therapeutic  F814-F825
                   approaches[J]. Eur J Pharmacol,2020,885:173503  [26] SONG J,XIA Y,YAN X,et al. Losartan accelerates the
             [15] WIVIOTT S D,RAZ I,BONACA M P,et al. Dapagliflozin  repair process of renal fibrosis in UUO mouse after the
                   and cardiovascular outcomes in type 2 diabetes[J]. N  surgical recanalization by upregulating the expression of
                   Engl J Med,2019,380(4):347-357                    Tregs[J]. Int Urol Nephrol,2019,51(11):2073-2081
             [16] PERKOVIC V,JARDINE M J,NEAL B,et al. Cana⁃    [27] KONG L,ANDRIKOPOULOS S,MACISAAC R J,et al.
                   gliflozin and renal outcomes in type 2 diabetes and ne⁃  Role of the adaptive immune system in diabetic kidney
                   phropathy[J]. N Engl J Med,2019,380(24):2295-2306  disease[J]. J Diabetes Investig,2022,13(2):213-226
             [17] 阳   皓,谭巧灵,王      岑,等. 达格列净对早期2型糖尿             [28] 褚   璇,赵   猛,孙    娟,等. 2 型糖尿病患者外周血 T
                   病肾病患者尿微量白蛋白和促炎症因子的影响[J]. 华                        淋巴细胞亚群表达与糖尿病肾脏疾病关系的研究[J].
                   中科技大学学报(医学版),2019,48(4):400-404                   中国糖尿病杂志,2021,29(12):902-906
             [18] NEUEN B L,OSHIMA M,AGARWAL R,et al. Sodium⁃   [29] WANG D,ZHANG Z,SI Z,et al. Dapagliflozin reverses
                   glucose cotransporter 2 inhibitors and risk of hyperkale⁃  the imbalance of T helper 17 and T regulatory cells by in⁃
                   mia in people with type 2 diabetes:a Meta⁃analysis of in⁃  hibiting SGK1 in a mouse model of diabetic kidney dis⁃
                   dividual participant data from randomized,controlled tri⁃  ease[J]. FEBS Open Bio,2021,11(5):1395-1405
                   als[J]. Circulation,2022,145(19):1460-1470   [30] 魏   晗,辛小军,王      曼,等. SGLT⁃2 抑制剂改善糖尿
             [19] CHAN Y,CHEN S,CHAO T,et al. Impact of the initial  病患者心血管疾病预后的研究进展[J]. 南京医科大学
                   decline in estimated glomerular filtration rate on the risk  学报(自然科学版),2020,40(5):773-778
                   of new⁃onset atrial fibrillation and adverse cardiovascular            [收稿日期] 2022-04-20
                   and renal events in patients with type 2 diabetes treated                   (责任编辑:蒋      莉)
   67   68   69   70   71   72   73   74   75   76   77